Mallinckrodt Plc Ordinary Share (MNK) 62.16 $MNK
Looking for Bargain Stocks? Pick These 5 with Low P/B Ratio
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 9:57AM CDT
The P/B ratio is used to calculate how much an investor needs to pay for each dollar of book value of a stock.
MNK: 62.16 (+0.26), PMC: 26.19 (-0.06), KEP: 26.19 (+0.12), HZNP: 18.35 (-0.54), SEM: 11.44 (+0.12)
Progenics Pharmaceuticals (PGNX) Jumps: Stock Up 9.3%
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 7:15AM CDT
Progenics Pharmaceuticals, Inc. (PGNX) shares rose over 9% in the last trading session.
MNK: 62.16 (+0.26), PGNX: 4.92 (-0.26)
Mallinckrodt plc To Report Third Quarter Fiscal 2016 Results On Aug. 2, 2016
PR Newswire - Tue Jun 21, 6:00AM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, will report third quarter fiscal 2016 results on Tuesday, Aug. 2, 2016.
MNK: 62.16 (+0.26)
Mallinckrodt Donates One Million Drug Deactivation Pouches To Support U.S. Fight Against Prescription Drug Abuse
PR Newswire - Thu Jun 16, 3:45PM CDT
Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty biopharmaceutical company, today announced that it will purchase and donate more than 1 million Deterra(TM) drug deactivation pouches to help combat one of the top public health threats in the U.S. today - abuse of prescription pain medications. Through this initiative, families can actively address concerns with the responsible use of pain medications and patient safety.
MNK: 62.16 (+0.26)
Mallinckrodt Submits Investigational New Drug Application for Synacthen® Depot
PR Newswire - Mon Jun 13, 6:00AM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, today announced it has submitted an Investigational New Drug (IND) application for Synacthen® Depot to the U.S. Food and Drug Administration (FDA). The company will pursue an indication for the drug in treatment of Duchenne muscular dystrophy (DMD). Synacthen Depot is a depot formulation of Synacthen (tetracosactide), a synthetic 24 amino acid melanocortin receptor agonist. Synacthen Depot is approved and marketed outside of the U.S. for certain autoimmune and inflammatory conditions, but has never been approved for use in patients in the U.S.
MNK: 62.16 (+0.26)
Mallinckrodt Presents New Data from 44-Week Open Label Extension Of Company-Sponsored H.P. Acthar® Gel Trial in Lupus
PR Newswire - Thu Jun 09, 4:05PM CDT
Researchers for Mallinckrodt plc (NYSE: MNK), a leading specialty biopharmaceutical company, today presented results from the 44-week open label extension (OLE) of its company-sponsored, two-part pilot study exploring the efficacy of H.P. Acthar® Gel (repository corticotropin injection) (RCI) in Systemic Lupus Erythematosus (SLE) patients with a history of persistently active disease. Acthar is approved by the U.S. Food and Drug Administration for use during an exacerbation or as a maintenance therapy in select patients with SLE. Study data were presented at the European League Against Rheumatism (EULAR) Annual Congress in London.
MNK: 62.16 (+0.26)
Mallinckrodt Donates 250,000 Drug Deactivation Systems to ACT Missouri to Support Fight Against Prescription Drug Abuse
PR Newswire - Mon May 23, 3:30PM CDT
Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty biopharmaceutical company, today announced that it has purchased and donated 250,000 drug deactivation systems to ACT Missouri to provide patients and caregivers a secure, convenient, and environmentally safe way to dispose of unused medications.
MNK: 62.16 (+0.26)
Mallinckrodt plc to Change Fiscal Year
PR Newswire - Wed May 18, 3:30PM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, today announced that its Board of Directors has approved a change in the company's fiscal year end to the last Friday in December from the last Friday in September.
MNK: 62.16 (+0.26)
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel for Rare Cause of Nephrotic Syndrome
PR Newswire - Tue May 17, 3:01PM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, today confirmed enrollment of the first patient in the company's Phase 4 clinical study assessing the efficacy of H.P. Acthar® Gel (repository corticotropin injection) for inducing remission of proteinuria due to treatment-resistant or treatment-intolerant idiopathic focal segmental glomerulosclerosis (FSGS). FSGS is a rare disease that can cause nephrotic syndrome, a serious kidney disorder.
MNK: 62.16 (+0.26)
The Medicines Co. Loss Wider, to Divest Cardiovascular Drugs
Zacks Equity Research - Zacks Investment Research - Tue May 10, 10:24AM CDT
The Medicines Company (MDCO) reported a wider-than-expected loss of $1.13 per share in the first quarter of 2016.
MNK: 62.16 (+0.26), MDCO: 35.82 (-0.80), ANIP: 54.26 (-1.47), NVS: 82.03 (+0.35)
The Zacks Analyst Blog Highlights: Fiat Chrysler Automobiles, Transocean Partners, Mallinckrodt Public Limited, Radian Group and Owens-Illinois
Zacks Equity Research - Zacks Investment Research - Fri May 06, 8:30AM CDT
The Zacks Analyst Blog Highlights: Fiat Chrysler Automobiles, Transocean Partners, Mallinckrodt Public Limited, Radian Group and Owens-Illinois
MNK: 62.16 (+0.26), RIGP: 12.41 (-0.01), RDN: 11.73 (+0.04), OI: 17.94 (+0.06), FCAU: 6.56 (-0.08)
Endocyte (ECYT) Reports Narrower than Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Thu May 05, 3:01PM CDT
Endocyte, Inc. (ECYT) reported a first-quarter 2016 loss of 24 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 26 cents and the year-ago loss of 26 cents.
MNK: 62.16 (+0.26), ECYT: 3.14 (-0.10), SHPG: 192.49 (-2.82), NKTR: 15.77 (+0.08)
5 High Earnings Yield Stocks for Rich Rewards
Zacks Equity Research - Zacks Investment Research - Thu May 05, 10:39AM CDT
You can use the Earnings Yield to compare a stock with other stocks and with fixed income securities.
MNK: 62.16 (+0.26), RIGP: 12.41 (-0.01), RDN: 11.73 (+0.04), OI: 17.94 (+0.06), FCAU: 6.56 (-0.08)
Company News for May 04, 2016
Zacks Equity Research - Zacks Investment Research - Wed May 04, 9:10AM CDT
Companies in the News are: TAP,CVS,MNK,CLX
MNK: 62.16 (+0.26), CLX: 137.06 (+0.84), CVS: 97.63 (+1.17), TAP: 101.20 (-0.20)
Mallinckrodt (MNK) Tops Q2 Earnings and Sales, Ups View
Zacks Equity Research - Zacks Investment Research - Tue May 03, 9:49AM CDT
Mallinckrodt (MNK) reported adjusted earnings of $2.01 per share in the second quarter of fiscal 2016 (ended Mar 25, 2016), beating the Zacks Consensus Estimate of $1.72.
MNK: 62.16 (+0.26), GILD: 85.75 (-0.88), MDCO: 35.82 (-0.80), AEGR: 1.58 (-0.03)
Mallinckrodt (MNK) Tops Q2 Earnings, Raises View Again
Ekta Bagri - Zacks Investment Research - Tue May 03, 5:56AM CDT
Mallinckrodt beat on earnings by a wide margin.
MNK: 62.16 (+0.26)
Mallinckrodt tops Street 2Q forecasts
Automated Insights - Tue May 03, 5:15AM CDT
DERBYSHIRE, Britain (AP) _ Mallinckrodt PLC (MNK) on Tuesday reported fiscal second-quarter profit of $118.3 million.
MNK: 62.16 (+0.26)
Mallinckrodt plc Reports Fiscal 2016 Second Quarter Results
PR Newswire - Tue May 03, 5:00AM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, today reported results for the second quarter of fiscal 2016. Amounts reported reflect presentation of the company's former contrast media and delivery systems (CMDS) business as a discontinued operation. Unless otherwise noted, all comparisons of fiscal 2016 second quarter or first half performance are to the comparable periods of fiscal 2015.
MNK: 62.16 (+0.26)
The Zacks Analyst Blog Highlights: Amgen, Johnson & Johnson, Pfizer, Mylan and Mallinckrodt
Zacks Equity Research - Zacks Investment Research - Mon May 02, 8:30AM CDT
The Zacks Analyst Blog Highlights: Amgen, Johnson & Johnson, Pfizer, Mylan and Mallinckrodt
MNK: 62.16 (+0.26), JNJ: 123.00 (+0.08), PFE: 36.31 (+0.07), MYL: 45.30 (+0.14), AMGN: 160.52 (-1.44)
3 Drug Stocks Reporting Early Next Week: PFE, MYL, MNK
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 9:23AM CDT
How will drug stocks Pfizer, Mylan, and Mallinckrodt fare when they report their earnings results on May 3?
MNK: 62.16 (+0.26), BIIB: 251.19 (-2.17), JNJ: 123.00 (+0.08), GILD: 85.75 (-0.88), PFE: 36.31 (+0.07), MYL: 45.30 (+0.14), AMGN: 160.52 (-1.44)
Looking for Bargain Stocks? Pick These 5 with Low P/B Ratio
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 9:57AM CDT
The P/B ratio is used to calculate how much an investor needs to pay for each dollar of book value of a stock.
MNK: 62.16 (+0.26), PMC: 26.19 (-0.06), KEP: 26.19 (+0.12), HZNP: 18.35 (-0.54), SEM: 11.44 (+0.12)
Progenics Pharmaceuticals (PGNX) Jumps: Stock Up 9.3%
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 7:15AM CDT
Progenics Pharmaceuticals, Inc. (PGNX) shares rose over 9% in the last trading session.
MNK: 62.16 (+0.26), PGNX: 4.92 (-0.26)
Mallinckrodt plc To Report Third Quarter Fiscal 2016 Results On Aug. 2, 2016
PR Newswire - Tue Jun 21, 6:00AM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, will report third quarter fiscal 2016 results on Tuesday, Aug. 2, 2016.
MNK: 62.16 (+0.26)
Mallinckrodt Donates One Million Drug Deactivation Pouches To Support U.S. Fight Against Prescription Drug Abuse
PR Newswire - Thu Jun 16, 3:45PM CDT
Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty biopharmaceutical company, today announced that it will purchase and donate more than 1 million Deterra(TM) drug deactivation pouches to help combat one of the top public health threats in the U.S. today - abuse of prescription pain medications. Through this initiative, families can actively address concerns with the responsible use of pain medications and patient safety.
MNK: 62.16 (+0.26)
Mallinckrodt Submits Investigational New Drug Application for Synacthen® Depot
PR Newswire - Mon Jun 13, 6:00AM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, today announced it has submitted an Investigational New Drug (IND) application for Synacthen® Depot to the U.S. Food and Drug Administration (FDA). The company will pursue an indication for the drug in treatment of Duchenne muscular dystrophy (DMD). Synacthen Depot is a depot formulation of Synacthen (tetracosactide), a synthetic 24 amino acid melanocortin receptor agonist. Synacthen Depot is approved and marketed outside of the U.S. for certain autoimmune and inflammatory conditions, but has never been approved for use in patients in the U.S.
MNK: 62.16 (+0.26)
Mallinckrodt Presents New Data from 44-Week Open Label Extension Of Company-Sponsored H.P. Acthar® Gel Trial in Lupus
PR Newswire - Thu Jun 09, 4:05PM CDT
Researchers for Mallinckrodt plc (NYSE: MNK), a leading specialty biopharmaceutical company, today presented results from the 44-week open label extension (OLE) of its company-sponsored, two-part pilot study exploring the efficacy of H.P. Acthar® Gel (repository corticotropin injection) (RCI) in Systemic Lupus Erythematosus (SLE) patients with a history of persistently active disease. Acthar is approved by the U.S. Food and Drug Administration for use during an exacerbation or as a maintenance therapy in select patients with SLE. Study data were presented at the European League Against Rheumatism (EULAR) Annual Congress in London.
MNK: 62.16 (+0.26)
Mallinckrodt Donates 250,000 Drug Deactivation Systems to ACT Missouri to Support Fight Against Prescription Drug Abuse
PR Newswire - Mon May 23, 3:30PM CDT
Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty biopharmaceutical company, today announced that it has purchased and donated 250,000 drug deactivation systems to ACT Missouri to provide patients and caregivers a secure, convenient, and environmentally safe way to dispose of unused medications.
MNK: 62.16 (+0.26)
Mallinckrodt plc to Change Fiscal Year
PR Newswire - Wed May 18, 3:30PM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, today announced that its Board of Directors has approved a change in the company's fiscal year end to the last Friday in December from the last Friday in September.
MNK: 62.16 (+0.26)
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel for Rare Cause of Nephrotic Syndrome
PR Newswire - Tue May 17, 3:01PM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, today confirmed enrollment of the first patient in the company's Phase 4 clinical study assessing the efficacy of H.P. Acthar® Gel (repository corticotropin injection) for inducing remission of proteinuria due to treatment-resistant or treatment-intolerant idiopathic focal segmental glomerulosclerosis (FSGS). FSGS is a rare disease that can cause nephrotic syndrome, a serious kidney disorder.
MNK: 62.16 (+0.26)
The Medicines Co. Loss Wider, to Divest Cardiovascular Drugs
Zacks Equity Research - Zacks Investment Research - Tue May 10, 10:24AM CDT
The Medicines Company (MDCO) reported a wider-than-expected loss of $1.13 per share in the first quarter of 2016.
MNK: 62.16 (+0.26), MDCO: 35.82 (-0.80), ANIP: 54.26 (-1.47), NVS: 82.03 (+0.35)
The Zacks Analyst Blog Highlights: Fiat Chrysler Automobiles, Transocean Partners, Mallinckrodt Public Limited, Radian Group and Owens-Illinois
Zacks Equity Research - Zacks Investment Research - Fri May 06, 8:30AM CDT
The Zacks Analyst Blog Highlights: Fiat Chrysler Automobiles, Transocean Partners, Mallinckrodt Public Limited, Radian Group and Owens-Illinois
MNK: 62.16 (+0.26), RIGP: 12.41 (-0.01), RDN: 11.73 (+0.04), OI: 17.94 (+0.06), FCAU: 6.56 (-0.08)
Endocyte (ECYT) Reports Narrower than Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Thu May 05, 3:01PM CDT
Endocyte, Inc. (ECYT) reported a first-quarter 2016 loss of 24 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 26 cents and the year-ago loss of 26 cents.
MNK: 62.16 (+0.26), ECYT: 3.14 (-0.10), SHPG: 192.49 (-2.82), NKTR: 15.77 (+0.08)
5 High Earnings Yield Stocks for Rich Rewards
Zacks Equity Research - Zacks Investment Research - Thu May 05, 10:39AM CDT
You can use the Earnings Yield to compare a stock with other stocks and with fixed income securities.
MNK: 62.16 (+0.26), RIGP: 12.41 (-0.01), RDN: 11.73 (+0.04), OI: 17.94 (+0.06), FCAU: 6.56 (-0.08)
Company News for May 04, 2016
Zacks Equity Research - Zacks Investment Research - Wed May 04, 9:10AM CDT
Companies in the News are: TAP,CVS,MNK,CLX
MNK: 62.16 (+0.26), CLX: 137.06 (+0.84), CVS: 97.63 (+1.17), TAP: 101.20 (-0.20)
Mallinckrodt (MNK) Tops Q2 Earnings and Sales, Ups View
Zacks Equity Research - Zacks Investment Research - Tue May 03, 9:49AM CDT
Mallinckrodt (MNK) reported adjusted earnings of $2.01 per share in the second quarter of fiscal 2016 (ended Mar 25, 2016), beating the Zacks Consensus Estimate of $1.72.
MNK: 62.16 (+0.26), GILD: 85.75 (-0.88), MDCO: 35.82 (-0.80), AEGR: 1.58 (-0.03)
Mallinckrodt (MNK) Tops Q2 Earnings, Raises View Again
Ekta Bagri - Zacks Investment Research - Tue May 03, 5:56AM CDT
Mallinckrodt beat on earnings by a wide margin.
MNK: 62.16 (+0.26)
Mallinckrodt tops Street 2Q forecasts
Automated Insights - Tue May 03, 5:15AM CDT
DERBYSHIRE, Britain (AP) _ Mallinckrodt PLC (MNK) on Tuesday reported fiscal second-quarter profit of $118.3 million.
MNK: 62.16 (+0.26)
Mallinckrodt plc Reports Fiscal 2016 Second Quarter Results
PR Newswire - Tue May 03, 5:00AM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, today reported results for the second quarter of fiscal 2016. Amounts reported reflect presentation of the company's former contrast media and delivery systems (CMDS) business as a discontinued operation. Unless otherwise noted, all comparisons of fiscal 2016 second quarter or first half performance are to the comparable periods of fiscal 2015.
MNK: 62.16 (+0.26)
The Zacks Analyst Blog Highlights: Amgen, Johnson & Johnson, Pfizer, Mylan and Mallinckrodt
Zacks Equity Research - Zacks Investment Research - Mon May 02, 8:30AM CDT
The Zacks Analyst Blog Highlights: Amgen, Johnson & Johnson, Pfizer, Mylan and Mallinckrodt
MNK: 62.16 (+0.26), JNJ: 123.00 (+0.08), PFE: 36.31 (+0.07), MYL: 45.30 (+0.14), AMGN: 160.52 (-1.44)
3 Drug Stocks Reporting Early Next Week: PFE, MYL, MNK
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 9:23AM CDT
How will drug stocks Pfizer, Mylan, and Mallinckrodt fare when they report their earnings results on May 3?
MNK: 62.16 (+0.26), BIIB: 251.19 (-2.17), JNJ: 123.00 (+0.08), GILD: 85.75 (-0.88), PFE: 36.31 (+0.07), MYL: 45.30 (+0.14), AMGN: 160.52 (-1.44)
